News

Drug Briefing: Ruxolitinib

Views: 25     Author: Unibest Industrial     Publish Time: 2024-04-25      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button


Query Drug:Ruxolitinib

Query Time:2024-04-25 09:12:38

*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.


About the Drug

Ruxolitinib is used in adults to treat myelofibrosis or polycythemia vera, which are bone marrow disorders that affect your body's ability to produce blood cells.

Ruxolitinib is also used to treat graft versus host disease in adults and children at least 12 years old.

Ruxolitinib is usually given after other treatments have failed.

Ruxolitinib may also be used for purposes not listed in this medication guide.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may be similar to the symptoms of myelofibrosis. 

Related Diseases

Disease(s) related to Ruxolitinib include:polycythemia-vera. In terms of each disease, here are other alternative drugs:

polycythemia-vera

Drug Name Rating Reviews Rx/OTC Brandname Drug?
hydroxyurea 5.2 9 Rx False
Jakafi 7.3 20 Rx True
ruxolitinib 7.3 23 Rx False
Besremi

Rx True
ropeginterferon alfa-2b

Rx False
peginterferon alfa-2a

Rx False

Reference: drugs.com

Extra Information on Drug and Diseases

Drug ruxolitinib

RXCUI: 1193326

May Treat

  • Primary Myelofibrosis

  • Polycythemia Vera

Similar Drugs

[may_treat] Polycythemia Vera

Source MEDRT

[may_treat] Primary Myelofibrosis

Source MEDRT

[Physiological Effect] Decreased Hematopoiesis

Source: MEDRT

[Phamacological Category] Kinase Inhibitor

Source DAILYMED

[Phamacological Category] Kinase Inhibitor

Source FDASPL

[Physiological Effect] Cellular Proliferation Alteration

Source: MEDRT

[Mechanism of Action] Janus Kinase Inhibitors

Source DAILYMED

[Mechanism of Action] Janus Kinase Inhibitors

Source FDASPL

[Mechanism of Action] Janus Kinase Inhibitors

Source MEDRT

[Phamacological Category] Janus Kinase Inhibitor

Source DAILYMED

[Phamacological Category] Janus Kinase Inhibitor

Source FDASPL

Drug ruxolitinib phosphate

RXCUI: 1193325

May Treat

  • Primary Myelofibrosis

  • Polycythemia Vera

Similar Drugs

[may_treat] Polycythemia Vera

Source MEDRT

[may_treat] Primary Myelofibrosis

Source MEDRT

[Physiological Effect] Decreased Hematopoiesis

Source: MEDRT

[Physiological Effect] Cellular Proliferation Alteration

Source: MEDRT

[Mechanism of Action] Janus Kinase Inhibitors

Source MEDRT

Orange Book

[Last update] 2024-03-08

Labelers

Ruxolitinib's Innovator is INCYTE CORP

Drug Products

The unique dosage forms from the innovator include:1. CREAM;TOPICAL;2. TABLET;ORAL.

Index Route Brand Name Labeler Approval Date Dosage
1 CREAM;TOPICAL OPZELURA INCYTE CORP Sep 21, 2021 EQ 1.5% BASE
2 TABLET;ORAL JAKAFI INCYTE CORP Nov 16, 2011 EQ 15MG BASE
3 TABLET;ORAL JAKAFI INCYTE CORP Nov 16, 2011 EQ 20MG BASE
4 TABLET;ORAL JAKAFI INCYTE CORP Nov 16, 2011 EQ 5MG BASE
5 TABLET;ORAL JAKAFI INCYTE CORP Nov 16, 2011 EQ 25MG BASE
6 TABLET;ORAL JAKAFI INCYTE CORP Nov 16, 2011 EQ 10MG BASE

Drug Patents

This drug still has 34 effective patents.

Patent Number Submission Date Expiration Date Drug Substance Patent? Drug Product Patent?
8829013 Sep 24, 2014 Jun 12, 2028

10016429 Jun 12, 2019 Jun 12, 2028

9814722 Jun 12, 2019 Dec 12, 2026

8822481 Oct 20, 2021 Jun 12, 2028

10610530 Oct 20, 2021 Jun 12, 2028

9079912 Oct 20, 2021 Dec 12, 2026

10869870 Oct 20, 2021 May 20, 2031

9974790 Oct 20, 2021 Dec 12, 2026

10639310 Oct 20, 2021 Dec 12, 2026

8722693 Oct 20, 2021 Jun 12, 2028 Y Y
7598257 Oct 20, 2021 Dec 24, 2027 Y Y
8415362 Oct 20, 2021 Dec 24, 2027 Y Y
10758543 Oct 20, 2021 May 20, 2031
Y
11219624 Feb 8, 2022 May 20, 2031
Y
11510923 Dec 16, 2022 Sep 4, 2040

11571425 Feb 28, 2023 May 20, 2031
Y
11602536 Mar 28, 2023 May 5, 2041

11590137 Mar 28, 2023 Sep 4, 2040

11590138 Mar 28, 2023 Jun 10, 2040

11590136 Mar 28, 2023 May 20, 2031

11219624*PED
Nov 20, 2031

7598257*PED
Jun 24, 2028

8415362*PED
Jun 24, 2028

8722693*PED
Dec 12, 2028

10758543*PED
Nov 20, 2031

9079912*PED
Jun 12, 2027

9974790*PED
Jun 12, 2027

10610530*PED
Dec 12, 2028

8822481*PED
Dec 12, 2028

10869870*PED
Nov 20, 2031

10639310*PED
Jun 12, 2027

8829013*PED
Dec 12, 2028

9814722*PED
Jun 12, 2027

10016429*PED
Dec 12, 2028


Ruxolitinib Patent Scope


Related Company's Product Pipelines

The innovator INCYTE CORP's portolio contains products with the following 2 API(s): PEMIGATINIB, RUXOLITINIB PHOSPHATE

The above products are related to 3 diseases: Cholangiocarcinoma, Primary Myelofibrosis, Polycythemia Vera

API Disease
PEMIGATINIB Cholangiocarcinoma
RUXOLITINIB PHOSPHATE Primary Myelofibrosis
RUXOLITINIB PHOSPHATE Polycythemia Vera

INCYTE CORP_disease_distribution_2024-04-25